All In Biotech

Drug Trial Radar · NCT01599806

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults

Last checked: Nov 20, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 641 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

641

Actual

Start

Oct 2012

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
May 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis

Conditions

  • Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Interventions

  • Ceftazidime - Avibactam ( CAZ-AVI)Drug

    Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes

  • DoripenemDrug

    500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes

  • Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)Drug

    Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

  • or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)Drug

    Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.
  2. Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.
  3. Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Locations

57 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Detroit, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Indiana, Pennsylvania

  • Research Site

    Rosario, Argentina

  • Research Site

    Pazardzhik, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Slavonski Brod, Croatia

  • Research Site

    Zadar, Croatia

  • Research Site

    Zagreb, Croatia

  • Research Site

    Liberec, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Hamburg, Germany

  • Research Site

    Haifa, Israel

  • Research Site

    Kfar Saba, Israel

  • Research Site

    Modena, Italy

  • Research Site

    Cuernavaca, MOR, Mexico

  • Research Site

    Guadalajara, Mexico

  • Research Site

    Zapopan, Mexico

  • Research Site

    Arequipa, Peru

  • Research Site

    Cercardo de Lima, Peru

  • Research Site

    Cusco, Peru

  • Research Site

    Lima, Peru

  • Research Site

    Trujillo, Peru

  • Research Site

    Bialystok, Poland

  • Research Site

    Sochaczew, Poland

  • Research Site

    Wroclaw, Poland

  • Research Site

    Bucharest, Romania

  • Research Site

    Oradea, Romania

  • Research Site

    Sibiu, Romania

  • Research Site

    Timișoara, Romania

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Smolensk, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Velikiy Novgorod, Russia

  • Research Site

    Busan, South Korea

  • Research Site

    Jeonnam, South Korea

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.